First AD

Second AD

Panelists discuss the ideal patient population for Janus kinase (JAK) inhibitors in alopecia treatment, addressing specific patient characteristics that may contraindicate their use.

Considerations Regarding Patient Selection for JAK Inhibitors

Video content above is prompted by the following:

What is the ideal patient population for use of JAK inhibitors for alopecia?

Are there certain patient characteristics that would compel you to not use JAK inhibitors?

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

JAK inhibitors have emerged as a promising treatment for alopecia, particularly in patients with moderate to severe forms of the condition. Ideal candidates are those who have not responded to conventional therapies and exhibit significant hair loss impacting their quality of life. However, caution is advised in patients with a history of malignancies, active infections, or those who are immunocompromised, as JAK inhibitors can modulate immune responses. Additionally, patients with a history of thromboembolic events or cardiovascular risk factors may require careful assessment before initiating treatment.

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

JAK Inhibitor Baricitinib for Treatment of Alopecia Areata